中国神经再生研究(英文版) ›› 2019, Vol. 14 ›› Issue (11): 1903-1904.doi: 10.4103/1673-5374.259613

• 观点:退行性病与再生 • 上一篇    下一篇

基于抗体的免疫疗法治疗帕金森病综合征

  

  • 出版日期:2019-11-15 发布日期:2019-11-15

Antibody-based immunotherapies for Parkinsonian syndromes

Lars Tönges 1,2, Maria Angela Samis Zella 1,3   

  1. 1Department of Neurology, St. Josef-Hospital, Ruhr-UniversityBochum, Bochum, Germany;
    2Neurodegeneration Research, Protein Research Unit Ruhr (PURE), Ruhr University Bochum, Bochum, Germany;
    3Department of Neurology, St. Josef-Hospital, Katholische Kliniken Ruhrhalbinsel, Contilia Gruppe, Essen, Germany
  • Online:2019-11-15 Published:2019-11-15
  • Contact: Lars T?nges, MD, lars.toenges@rub.de.

摘要:

orcid: 0000-0002-0815-9820 (Maria Angela Samis Zella)
          0000-0001-6621-144X (Lars Tönges)

Abstract:

What is the rationale for immunotherapies in Parkinsonian syndromes (PS)? PS are neurodegenerative diseases which are clinically characterized by a hypokinetic phenotype in combination with additional motor and non-motor symptoms. One major pathological hallmark of all PS consists of a non-physiological detrimental accumulation of protein aggregates which appear intracellularly in neurons and glial cells but also in the extracellular space. Depending on the pathogenic protein, PS can be divided into synucleinopathies, characterized by aggregation of the protein alpha-Synuclein (aSyn), and tauopathies, characterized by aggregation of the protein Tau. Clinical syndromes of synucleinopathies include Parkinson’s disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies, and tauopathies include progressive supranuclear palsy (PSP) and corticobasal degeneration.